221 related articles for article (PubMed ID: 24372906)
1. Twelve-month medication persistence in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
Koh JS; Cho KJ; Kim HS; Kim JC
Int J Clin Pract; 2014 Feb; 68(2):197-202. PubMed ID: 24372906
[TBL] [Abstract][Full Text] [Related]
2. Re: Twelve-Month Medication Persistence in Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia.
Kaplan SA
J Urol; 2015 Oct; 194(4):1056. PubMed ID: 26382807
[No Abstract] [Full Text] [Related]
3. Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study.
Cindolo L; Pirozzi L; Fanizza C; Romero M; Tubaro A; Autorino R; De Nunzio C; Schips L
Eur Urol; 2015 Sep; 68(3):418-25. PubMed ID: 25465970
[TBL] [Abstract][Full Text] [Related]
4. Drug adherence and drug-related problems in pharmacotherapy for lower urinary tract symptoms related to benign prostatic hyperplasia.
Zabkowski T; Saracyn M
J Physiol Pharmacol; 2018 Aug; 69(4):. PubMed ID: 30552307
[TBL] [Abstract][Full Text] [Related]
5. A retrospective study of treatment persistence and adherence to α-blocker plus antimuscarinic combination therapies, in men with LUTS/BPH in the Netherlands.
Drake MJ; Bowditch S; Arbe E; Hakimi Z; Guelfucci F; Amri I; Nazir J
BMC Urol; 2017 May; 17(1):36. PubMed ID: 28532455
[TBL] [Abstract][Full Text] [Related]
6. Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard?
Silva J; Silva CM; Cruz F
Curr Opin Urol; 2014 Jan; 24(1):21-8. PubMed ID: 24231531
[TBL] [Abstract][Full Text] [Related]
7. Patient's adherence on pharmacological therapy for benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS) is different: is combination therapy better than monotherapy?
Cindolo L; Pirozzi L; Sountoulides P; Fanizza C; Romero M; Castellan P; Antonelli A; Simeone C; Tubaro A; de Nunzio C; Schips L
BMC Urol; 2015 Sep; 15():96. PubMed ID: 26391357
[TBL] [Abstract][Full Text] [Related]
8. Increased population use of medications for male lower urinary tract symptoms/benign prostatic hyperplasia correlates with changes in indications for transurethral resection of the prostate.
Ingimarsson JP; Isaksson HJ; Sigbjarnarson HP; Gudmundsson J; Geirsson G
Scand J Urol; 2014 Feb; 48(1):73-8. PubMed ID: 23924152
[TBL] [Abstract][Full Text] [Related]
9. Early symptom improvement and discontinuation of 5-α-reductase inhibitor (5ARI) therapy in patients with benign prostatic hyperplasia (BPH).
Kruep EJ; Phillips E; Hogue S; Eaddy M
Ann Pharmacother; 2014 Mar; 48(3):343-8. PubMed ID: 24311727
[TBL] [Abstract][Full Text] [Related]
10. The prostaglandin pathway is activated in patients who fail medical therapy for benign prostatic hyperplasia with lower urinary tract symptoms.
Jin R; Strand DW; Forbes CM; Case T; Cates JMM; Liu Q; Ramirez-Solano M; Milne GL; Sanchez S; Wang ZY; Bjorling DE; Miller NL; Matusik RJ
Prostate; 2021 Sep; 81(13):944-955. PubMed ID: 34288015
[TBL] [Abstract][Full Text] [Related]
11. [Initial assessment, follow-up and treatment of lower urinary tract symptoms related to benign prostatic hyperplasia: guidelines of the LUTS committee of the French Urological Association].
Descazeaud A; Robert G; Delongchamps NB; Cornu JN; Saussine C; Haillot O; Devonec M; Fourmarier M; Ballereau C; Lukacs B; Dumonceau O; Azzouzi AR; Faix A; Desgrandchamps F; de la Taille A;
Prog Urol; 2012 Dec; 22(16):977-88. PubMed ID: 23178093
[TBL] [Abstract][Full Text] [Related]
12. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.
Gacci M; Eardley I; Giuliano F; Hatzichristou D; Kaplan SA; Maggi M; McVary KT; Mirone V; Porst H; Roehrborn CG
Eur Urol; 2011 Oct; 60(4):809-25. PubMed ID: 21726934
[TBL] [Abstract][Full Text] [Related]
13. Demographic and comorbidity profile of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a real-life clinical setting: Are 5-alpha-reductase inhibitor consumers different?
Fusco F; Arcaniolo D; Creta M; Piccinocchi G; Arpino G; Laringe M; Piccinocchi R; Longo N; Verze P; Mangiapia F; Imperatore V; Mirone V
World J Urol; 2015 May; 33(5):685-9. PubMed ID: 25491675
[TBL] [Abstract][Full Text] [Related]
14. Current benign prostatic hyperplasia treatment: impact on sexual function and management of related sexual adverse events.
Mirone V; Sessa A; Giuliano F; Berges R; Kirby M; Moncada I
Int J Clin Pract; 2011 Sep; 65(9):1005-13. PubMed ID: 21718399
[TBL] [Abstract][Full Text] [Related]
15. Patient characteristics and treatment patterns for patients with benign prostatic hyperplasia, erectile dysfunction or co-occurring benign prostatic hyperplasia and erectile dysfunction in general practices in the UK: a retrospective observational study.
Ilo D; Raluy-Callado M; Graham-Clarke P; Sadasivan R; Birt J; Donaldson R; Zhu E; Kirby MG; Neasham D
Int J Clin Pract; 2015 Aug; 69(8):853-62. PubMed ID: 26011100
[TBL] [Abstract][Full Text] [Related]
16. Medical therapy for benign prostatic hyperplasia: a review.
Van Asseldonk B; Barkin J; Elterman DS
Can J Urol; 2015 Oct; 22 Suppl 1():7-17. PubMed ID: 26497339
[TBL] [Abstract][Full Text] [Related]
17. Clinical progression, acute urinary retention, prostate-related surgeries, and costs in patients with benign prostatic hyperplasia taking early versus delayed combination 5α-reductase inhibitor therapy and α-blocker therapy: a retrospective analysis.
Morlock R; Goodwin B; Gomez Rey G; Eaddy M
Clin Ther; 2013 May; 35(5):624-33. PubMed ID: 23583026
[TBL] [Abstract][Full Text] [Related]
18. Treatment strategies, patterns of drug use and treatment discontinuation in men with LUTS suggestive of benign prostatic hyperplasia: the Triumph project.
Verhamme KM; Dieleman JP; Bleumink GS; Bosch JL; Stricker BH; Sturkenboom MC
Eur Urol; 2003 Nov; 44(5):539-45. PubMed ID: 14572751
[TBL] [Abstract][Full Text] [Related]
19. Understanding patient and physician perceptions of benign prostatic hyperplasia in Asia Pacific, Latin America and the Commonwealth of Independent States: the Prostate Research on Behaviour and Education (PROBE) II survey.
Ertel P; Adalig B; Demircan I; Lartey B; Manyak MJ
Int J Clin Pract; 2016 Oct; 70(10):870-880. PubMed ID: 27774780
[TBL] [Abstract][Full Text] [Related]
20. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 4-year data from the CombAT study.
Montorsi F; Henkel T; Geboers A; Mirone V; Arrosagaray P; Morrill B; Black L
Int J Clin Pract; 2010 Jul; 64(8):1042-51. PubMed ID: 20487046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]